“Circadian Function and Cardio-Metabolic Risk in Adrenal Insufficiency: A Case Control Study”

Learning Objectives:

1.  Discuss misalignment between central and peripheral clocks and the potential adverse effects on metabolism and cardiovascular function.

2.  Discuss how patients with adrenal insufficiency may be at increased risk for circadian misalignment and cardio-metabolic dysfunction.

3.  Discuss 24 hour profiles of cortisol, glucose, and insulin patients with adrenal insufficiency as evidence of potential circadian misalignment.

Presented by:  Monika Darji, M.D.

Endocrinology Fellow, The University of Chicago

and

“Understanding Genetics of Lipid Disorders and Role of Apo A5 Mutations”

Learning Objectives:

1.  Significance of genetic tests in patients at high risk for dyslipidemia in understanding cardiac risks.

2.  Use of gene variants to identify individuals at higher risk for dyslipidemia for interventions.

3.  Discuss protective genes for reducing risk of MI and use in pharmacology.

Presented by:  Sonaina Imtiaz, M.B., B.S.

Endocrinology Fellow, The University of Chicago

and

 “Advancing Understanding of GCK-MODY in Pregnancy in a Multi-ethnic U.S. Population”

Project #1 Learning Objectives:

1.  Review the genetics, pathophysiology, and clinical presentation of GCK-MODY.

2.  Evaluate the current recommendations for management of GCK-MODY during pregnancy based on data from women with GCK-MODY from the US Monogenic Diabetes Registry.

3.  Understand screening strategies for identifying GCK-MODY amongst women with gestational diabetes (GDM).

Presented by:  Laura Dickens, M.D.

Clinical Instructor and Endocrinology Fellow, The University of Chicago

“Can Bone Loss Following Denosumab Discontinuation be Prevented by Bisphosphonates?”

Project #2 Learning Objectives:

1.  Review denosumab therapy for osteoporosis and understand the risks of bone loss and vertebral fractures after denosumab discontinuation.

2.  Review existing literature about sequential therapy after denosumab discontinuation.

3.  Discuss strategies to evaluate the efficacy of oral and IV bisphosphonates for preventing bone loss after denosumab discontinuation.

Presented by:  Laura Dickens, M.D.

Clinical Instructor and Endocrinology Fellow, The University of Chicago